BACK TO TOP

Articles

Dacomitinib with or without dose titration in treatment naïve advanced EGFR mutated NSCLC – primary analysis of the ATORG-003 phase 2 trial
Tan AC, Kim TM, Zhou S, Lim YN, Ho GF, Tho LM, Reungwetwattana T, Prasongsook N, Lee S, Tan SH, Kim DW, Mok TSK, Tan DSW, Loong HHF.
JTO Clin Res Rep. 2026; 101027. Published online June 2026, https://doi.org/10.1016/j.jtocrr.2026.101027
Consensus Statement on ctDNA Minimal Residual Disease Testing in Early Stage NSCLC: A Delphi Study by the Asian Thoracic Oncology Research Group
Tan AC, Liao BC, Li MSC, Lee DDW, Uehara Y, Thamlikitkul L, Zhang JT, Zheng M, Lee CK, Pavlakis N, John T, Soo RA, Skanderup A, Voon PJ, Ahn BC, Park S, Hayashi H, Goto Y, Horinouchi H, Yatabe Y, Reungwetwattana T, Yang JCH, Kim DW, Mok TSK, Tan DSW, Wu YL, Ahn MJ.
J Thorac Oncol, 2026; 103696. Published online 26 March 2026, https://doi.org/10.1016/j.jtho.2026.103696
Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer
Saw SPL, Zhong WZ, Fu R, Li MSC, Goto Y, Fox SB, Yatabe Y, Ong BH, Ng CSH, Lee DDW, Pham CP, Park IK, Yang JCH, Tsuboi M, Tho LM, John T, Hsu HH, Tan DSW, Mok TSK, Reungwetwattana T, Singh N
Lung Cancer, 2025; 200, 108076. Published online February 2025, https://doi.org/10.1016/j.lungcan.2024.108076
Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations
Ahn MJ, Mendoza MJL, Pavlakis N, Kato T, Soo RA, Kim DW, Liam CK, Hsia TC, Lee CK, Reungwetwattana T, Geater S, Chan OSH, Prasongsook N, Solomon BJ, Nguyen TTH, Kozuki T, Yang JCH, Wu YL, Mok TSK, Tan DSW, Yatabe Y.
Clinical Lung Cancer,2022; 23(8):670-685. Published online December 2022, https://doi.org/10.1016/j.cllc.2022.07.012
Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG005)
Lee J, Tan AC, Zhou S, Yoon S, Liu S, Masuda K, Hayashi H, Batra U, Kim DW, Goto Y, Tan SH, Wu YL, Lee DH, Tan DSW, Ahn MJ.
JTO Clin Res Rep. 2022; 3:100261. Published online: 04 December 2021, https://www.jtocrr.org/article/S2666-3643(21)00120-X/fulltext
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III Non-Small Cell Lung Cancer
Tan WL, Chua KLM, J Lin, Chan A, Ho GF, Tho LM, V Lee, Reungwetwattana T, Soo RA, Yang JCY, Kim DW, Ahn YC, Onishi H, Ahn MJ, Mok TSK, Tan DSW, Yang F.
J Thorac Oncol, 2019 Nov 13. Pii: S1556-0864(19)33640-8. Published online: 13 November 2019, https://doi.org/10.1016/j.jtho.2019.10.022

Poster Presentation

Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC: A Delphi study by the Asian Thoracic Oncology Research Group
Tan AC, Liao BC, Li MSC, Lee DDW, Uehara Y, Thamlikitkul L, Zhang JT, Kim DW, Mok TSK, Tan DSW, Wu YL, Ahn MJ, ATORG MRD Consensus Group Members
J Clin Oncol, (2026); 44(19), 289-289. Published online 23 June 2026, https://doi.org/10.1200/JCO.2026.44.19_suppl.289
638P Dacomitinib with or without dose titration in treatment naïve advanced EGFR mutated NSCLC: Primary analysis of the ATORG-003 phase II trial
Tan AC, Kim TM, Zhou S, Lim YN, Ho GF, Tho LM, Reungwetwattana T, Prasongsook N, Lee S, Tan SH, Kim DW, Mok TSK, Tan DSW, Loong HHF.
Annals of Oncology, 2024; 35(4) S1641. Published online December 2024, https://doi.org/10.1016/j.annonc.2024.10.671
362P Intracranial activity of dacomitinib in treatment naïve advanced EGFR mutated non-small cell lung cancer (NSCLC): Prespecified subgroup analysis of the ATORG-003 trial
Tan AC, Kim DW, Reungwetwattana T, Yueh Ni L, Ho GF, Tho LM, Prasongsook N, Lee S, Mok TSK, Tan DSW, Loong HHF.
Annals of Oncology, 2022; 33(9)S1582-S1583. Published online: 01 November 2022, https://doi.org/10.1016/j.annonc.2022.10.400
Molecular profiling of non-small cell lung cancer (NSCLC) in Asia with targeted next-generation sequencing (NGS): Interim analysis of a co-operative group study (ATORG001)
Tan AC, Loong HHF, Ho GF, Seet A, Chiam B, Cheah DQ, Tan GS, Lim KH, Yang JCH, Mok TSK, Kim DW, Tan DSW.
Annals of Oncology, 2019; 30(9)IX126. Published online: 01 November 2019, https://doi.org/10.1093/annonc/mdz431.010
P2.14-20 ATORG-003: Dacomitinib With or Without Dose Titration as First-Line Therapy for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)
Tan AC, Mok TSK, Kim DW, Yang JCH, Lee CK, Soo RA, Reungwetwattana T, Tan DSW, Loong HHF
J Thorac Oncol, 2019; 14(10) S836-S837. Published online October 2019, https://doi.org/10.1016/j.jtho.2019.08.1805